Fluphenazine enanthate
Modify Date: 2024-01-04 09:14:29
Fluphenazine enanthate structure
|
Common Name | Fluphenazine enanthate | ||
|---|---|---|---|---|
| CAS Number | 2746-81-8 | Molecular Weight | 549.69100 | |
| Density | 1.181g/cm3 | Boiling Point | 629.4ºC at 760mmHg | |
| Molecular Formula | C29H38F3N3O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 334.4ºC | |
Use of Fluphenazine enanthateFluphenazine enanthate is the first long-acting injectable (LAI) antipsychotic for the treatment of schizophrenia[1][2]. |
| Name | 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl heptanoate |
|---|---|
| Synonym | More Synonyms |
| Description | Fluphenazine enanthate is the first long-acting injectable (LAI) antipsychotic for the treatment of schizophrenia[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Fluphenazine enanthate (2,4, 8 mg/kg; IM) significant inhibition of the avoidance performance is observed as long as 16, 23, and 28 days, respectively[1]. Fluphenazine enanthate (8 mg/kg) drinking behavior is almost completely suppressed for 24 hours immediately following the administration[1]. Fluphenazine enanthate (8 mg/kg) produces transient body weight Iosses in the rats[1]. Animal Model: Fifty-four male adult rats of Wistar strain[1] Dosage: 2, 4, and 8 mg/kg Administration: Index medicus (IM ) Result: Three doses of Fluphenazine enanthate significant inhibition of the avoidance performance was observed as long as 16, 23, and 28 days, respectively. |
| References |
| Density | 1.181g/cm3 |
|---|---|
| Boiling Point | 629.4ºC at 760mmHg |
| Molecular Formula | C29H38F3N3O2S |
| Molecular Weight | 549.69100 |
| Flash Point | 334.4ºC |
| Exact Mass | 549.26400 |
| PSA | 61.32000 |
| LogP | 6.77020 |
| Vapour Pressure | 9.41E-16mmHg at 25°C |
| Index of Refraction | 1.544 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| RIDADR | UN 3249 |
|---|---|
| Packaging Group | III |
| Hazard Class | 6.1(b) |
|
Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Int. Clin. Psychopharmacol. 28(5) , 261-6, (2013) Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to exami... |
|
|
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Schizophr. Res. 119(1-3) , 153-9, (2010) This study aimed to characterize the inpatient utilization of depot antipsychotics.The characteristics of adults with schizophrenia or schizoaffective disorder, hospitalized for at least 28 days, and ... |
|
|
Multiple congenital abnormalities in a newborn boy associated with maternal use of fluphenazine enanthate and other drugs during pregnancy.
Acta Paediatr. Scand. 71(2) , 335-8, (1982) A boy was born with a short sloping forehead, wide metopic suture, persistent metopic fontanelle, telecanthus, ocular hypertelorism, nystagmoid eye movements, bilateral cleft lip and palate, imperfora... |
| Fluphenazine enantate |
| 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl heptanoate |
| Fluphenazinenanthat |
| Fluphenanzin-aenanthat |
| 2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl heptanoate |
| Fluphenazin-aenanthsaeureester |
| 4-<3-<2-Trifluormethyl-phenothiazinyl-(10)>-propyl>-1-(2-hydroxy-ethyl)-piperazin-heptanoat |
| 1-heptanoyloxy-2-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethane |
| Moditen-retard |
| Prolixin Enanthate |
| fluphenazine enanthate |
| fluphenazine O-enantate |
| Eutimox |
| EINECS 220-385-0 |